0001209191-16-156690.txt : 20161223
0001209191-16-156690.hdr.sgml : 20161223
20161223171116
ACCESSION NUMBER: 0001209191-16-156690
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161223
FILED AS OF DATE: 20161223
DATE AS OF CHANGE: 20161223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC
CENTRAL INDEX KEY: 0001175505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260038620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-365-5600
MAIL ADDRESS:
STREET 1: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Lewis T
CENTRAL INDEX KEY: 0001475714
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36070
FILM NUMBER: 162069379
MAIL ADDRESS:
STREET 1: C/O FIVE PRIME THERAPEUTICS, INC.
STREET 2: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-12-23
0
0001175505
FIVE PRIME THERAPEUTICS INC
FPRX
0001475714
Williams Lewis T
TWO CORPORATE DRIVE
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President, CEO and Chairman
Common Stock
2016-12-23
4
M
0
155
4.56
A
434047
D
Common Stock
2016-12-23
4
M
0
19
6.89
A
434066
D
Common Stock
2016-12-23
4
M
0
10
8.49
A
434076
D
Common Stock
2016-12-23
4
M
0
29816
5.54
A
463892
D
Common Stock
2016-12-23
4
S
0
29700
50.49
D
434192
D
Common Stock
2016-12-23
4
S
0
300
51.02
D
433892
D
Employee Stock Option (right to buy)
4.56
2016-12-23
4
M
0
155
0.00
D
2019-04-15
Common Stock
155
91217
D
Employee Stock Option (right to buy)
6.89
2016-12-23
4
M
0
19
0.00
D
2020-07-28
Common Stock
19
14438
D
Employee Stock Option (right to buy)
8.49
2016-12-23
4
M
0
10
0.00
D
2021-10-19
Common Stock
10
16349
D
Employee Stock Option (right to buy)
5.54
2016-12-23
4
M
0
29816
0.00
D
2022-07-15
Common Stock
29816
31159
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2016.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.04, inclusive.
This option is fully vested and immediately exercisable.
/s/ Francis Sarena, Attorney-in-fact
2016-12-23